Cardioprotective functional effects of The Semelil (ANGIPARS™) in rabbits with experimental chronic myocardial infarction

Objectives: One of the prominent causes of mortality in worldwide is myocardial infarction. Some herbal medicineshave been utilized for the management of myocardial infarction. This investigation was planned to studythe cardioprotective influences of Semelil (ANGIPARS™), a novel herbal medicine, in male rabbits.Materials Methods: Twenty five white rabbits (New Zealand model) were fortuitously distributed into five groups: control vehicle (n=5); shamoperation (n=5); shamoperation vehicle (n=5); ischemia vehicle (n=5); Angipars 10 mg/kg (n=5). Ischemia was formed by complete blockage of Left Anterior Descending Coronary Artery (LAD). Angipars 10 mg/kg was injected for two weeks intraperitoneally in treatment group. Cardiac function on the first day and thirty day after LAD blockage were assessed for plasma level of myocardial enzymes, echocardiography (ECHO) and electrocardiography (ECG) in each group.Results Conclusion: The presentinvestigation revealed that Semelil had prominent role in improving serum level of SGOT, SGPT, CK, CK-MB, LDH, troponin T and cardiac function in Semelil 10 mg/kg group (p 0.05). After echocardiographic analysis at the first day and thirty dayafter MI, the rabbits in Semelil group had better cardiac function compared to ischemic rabbits. The results display in treatment group significant ameliorationon ejection fraction (from 45.1 ± 2.1 to 65.5 ± 5.6), LVFS (from 26.7 ± 2.72 to 38.8±4.5) and LVEDV (from 7.75 ± 1.19 to 11.27 ± 2.1) than ischemic group. The ECG on ischemic and Semelil groups displayed a typical characteristic of myocardial infarction in first day after MI. Semelil10 mg/kgin thirty day after MI could mend the ECG pattern. Theoutcomes display that cardio-protective influences of Semelil (ANGIPARS™) can be mediated by anti-oxidant and anti-inflammatory effects.